Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases

Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases
A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — for the diagnosis and treatment of neurodegenerative diseases, including Parkinson’s disease. Radiochemicals are compounds prepared with radioactive elements that are used for medical applications, such as tracers in positron emission tomography ... read more
Source: Parkinson’s News TodayPublished on 2020-02-06By Patricia Inacio, PhD